BioAdaptives, Inc. engages in marketing, investigating, and distributing natural plant and algal-based products that improve health and wellness for humans and animals. The company is headquartered in Las Vegas, Nevada and currently employs 1 full-time employees. The company went IPO on 2014-07-09. The Company’s core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products in development include a weight management supplement in a human clinical trial, Zeranovia. Zeranovia is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. Xcellara regenerative stem cell activator is in production. Xcellara is its regenerative wellness solution, to enhance performance, accelerate recovery, and revitalize health. PawPa Regen is the canine treat stem cell activator. PawPa Regen supports anti-aging and wellness. Its other products include MyndMed and Wynovia. MyndMed is designed to optimize multiple neurotransmitter systems and neuroprotective pathways.
How did BDPT's recent EPS compare to expectations?
The most recent EPS for BioAdaptives Inc is $, expectations of $.
How did BioAdaptives Inc BDPT's revenue perform in the last quarter?
BioAdaptives Inc revenue for the last quarter is $
What is the revenue estimate for BioAdaptives Inc?
According to of Wall street analyst, the revenue estimate of BioAdaptives Inc range from $ to $
What's the earning quality score for BioAdaptives Inc?
BioAdaptives Inc has a earning quality score of B+/46.10346. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does BioAdaptives Inc report earnings?
BioAdaptives Inc next earnings report is expected in
What are BioAdaptives Inc's expected earnings?
BioAdaptives Inc expected earnings is $, according to wall-street analysts.
Did BioAdaptives Inc beat earnings expectations?
BioAdaptives Inc recent earnings of $ expectations.